Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Transthyretin amyloidoses].

N Magy-Bertrand1

  • 1Service de médecine interne et immunologie clinique, CHU Jean-Minjoz, 2, boulevard Fleming, 25030 Besançon, France. nmagy@chu-besancon.fr

La Revue De Medecine Interne
|February 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.

The British journal of dermatology·2021
Same author

Electrostatic wipes as simple and reliable methods for influenza virus airborne detection.

The Journal of hospital infection·2020
Same author

[A persistent acrocyanosis in a 55 year-old woman].

La Revue de medecine interne·2019
Same author

[Eosinopenia in 2018].

La Revue de medecine interne·2018
Same author

[Swelling of the scalp].

La Revue de medecine interne·2016
Same author

[Prevention of infections in adults and adolescents with systemic lupus erythematosus: Guidelines for the clinical practice based on the literature and expert opinion].

La Revue de medecine interne·2016
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Transthyretin amyloidosis, a common condition, presents in familial and senile forms. Liver transplantation offers effective treatment for transthyretin amyloidosis, with new therapies targeting amyloid deposit formation under development.

Area of Science:

  • Transthyretin (TTR) protein structure and function in amyloidosis.
  • Molecular basis of familial and senile transthyretin amyloidosis.
  • Biochemical properties of TTR mutations leading to amyloid formation.

Context:

  • Transthyretin amyloidoses are the most prevalent forms of amyloidosis.
  • Familial transthyretin amyloidosis arises from mutated TTR, while senile amyloidosis involves wild-type TTR.
  • Clinical manifestations range from aggressive neuropathy and cardiomyopathy to milder cardiac symptoms.

Purpose:

  • To review the molecular, clinical, and evolutionary features of both familial and senile transthyretin amyloidoses.
  • To differentiate between the two types of transthyretin amyloidosis.
  • To provide an overview of current and emerging treatment strategies.

Summary:

Related Experiment Videos

  • Transthyretin amyloidosis encompasses familial (mutated TTR) and senile (wild-type TTR) forms, differing in clinical severity.
  • Molecular diagnostics are crucial for distinguishing between these types.
  • Liver transplantation effectively halts mutated TTR production, and novel therapies aim to inhibit amyloid deposition.

    • Impact:

    • Liver transplantation represents a significant therapeutic advance for transthyretin amyloidosis.
    • Emerging treatments, including P component analogs and TTR stabilizers, offer future therapeutic avenues.
    • Improved understanding of TTR amyloidosis facilitates better patient management and therapeutic development.